KRKNF -- Ultrathink: The Subsea Arms Race and the Price of Ambition

The Core Question

What is Kraken Robotics, really? Strip away the NATO contracts, the synthetic aperture sonar jargon, the defense spending tailwinds, and the breathless comparisons to Palantir. What remains?

A company that makes sonar equipment and underwater batteries, headquartered in Newfoundland, Canada, that has grown remarkably fast from nothing to C$102 million in revenue, and which now proposes to triple its size by acquiring a British subsea technology group for $615 million.

The question is not whether Kraken makes good sonar. It does. The AquaPix synthetic aperture sonar and KATFISH towed system are genuinely differentiated -- 2x2 centimeter resolution at 10 knots, deployed on NATO mine hunting vessels. This is not vapor-ware. Polish Navy ships use it. The question is not whether the market opportunity is real. It is. NATO countries are scrambling to modernize undersea warfare capabilities. Subsea infrastructure monitoring is a growing market. Autonomous underwater vehicles need sensors, batteries, and software. The global underwater robotics market is projected to reach $9-10 billion by 2030.

The real question -- the Buffett question -- is this: At what price does a genuine technological capability with a narrow moat and a transformational but risky acquisition become a good investment?

And the answer, unfortunately, is not today's price.

Moat Meditation

The most interesting aspect of Kraken's competitive position is how the moat is constructed. In most defense companies, the moat comes from scale, relationships, and the sheer complexity of prime contracting. Lockheed Martin's moat is not that it builds the best fighter jet -- it is that the F-35 program employs 300,000 people across 48 states, making it politically impossible to cancel.

Kraken's moat is different. It is technological and integrative. The AquaPix synthetic aperture sonar produces imagery that is demonstrably superior to conventional side-scan sonar. The KATFISH system can produce this imagery while being towed at speed, which is a meaningful operational advantage for mine countermeasures -- you can survey more ocean floor in less time. The SeaPower batteries enable longer endurance for autonomous underwater vehicles. And the subsea LiDAR systems (from the 3D at Depth acquisition) provide complementary optical imaging.

Post-Covelya, add Sonardyne's navigation, positioning, and communications systems, and you have what management calls "the most complete subsea technology stack" -- power, sensors, navigation, communications, imaging, and software for autonomous underwater platforms.

This is a real competitive advantage. But is it durable?

Here is where I pause. Technology moats in defense have a peculiar characteristic: they are real but time-limited. Today's best sonar becomes tomorrow's baseline. The question is not whether Kraken's SAS is the best available -- it is whether the gap can be maintained as competitors invest. Kongsberg Maritime alone has annual R&D spending that exceeds Kraken's entire revenue. Thales and L3Harris have deep pockets and their own synthetic aperture programs.

What protects Kraken is not the sonar alone -- it is the qualification process. Once a military customer has tested, qualified, and integrated a sonar system into their mine countermeasures operations, they face enormous switching costs. Requalification takes years. Operational doctrine must be rewritten. Training manuals must be revised. Maintenance supply chains must be rebuilt. This is why the Polish Navy's adoption of KATFISH in 2020, and their subsequent reorder in 2026, is so significant. It is not just a sale -- it is a sticky, reordering customer that validates the product in the harshest possible environment.

The Covelya acquisition, if successful, could meaningfully widen the moat. Sonardyne has 50 years of subsea technology experience and 700+ customers. The combination of Kraken's sensors/batteries with Sonardyne's navigation/positioning creates a platform that would be genuinely difficult to replicate from scratch. But "if successful" is doing a lot of heavy lifting in that sentence.

Moat verdict: Narrow, defensible in the niche, with potential to widen. Not Wide. Not yet.

The Owner's Mindset

Would Warren Buffett own this business for 20 years? Almost certainly not.

Buffett has consistently avoided defense contractors because of their dependence on government spending -- "I don't want to own a business where a vote in Congress can halve my revenue." He has avoided technology companies with unproven moats. He has avoided companies in the midst of transformational acquisitions. He has avoided companies that are barely profitable and cash flow negative. Kraken checks every one of these disqualifying boxes.

But Buffett's framework is not the only valid one. Charlie Munger might see something here -- a company with genuine intellectual property, in a market with secular tailwinds, where the "intelligent fanatic" founder has been replaced by a competent professional manager. Munger paid up for quality when he saw enduring advantages.

The problem is that even Munger never paid 60x EBITDA for a $100 million revenue company that just missed its guidance by 20%. Munger paid up for Costco at 25x earnings because the moat was demonstrably Wide and the business was self-funding its growth. Kraken is funding its growth by issuing shares -- lots of them. The share count has gone from 182 million to 294 million in four years, and will be approximately 357 million after the Covelya deal. That is nearly a 100% dilution in five years.

If you are buying Kraken at C$8.42, you are not buying a Munger-style quality compounder. You are making a bet that: (a) the Covelya integration will succeed, (b) combined revenue will exceed C$400M by 2027, (c) margins will hold at 24%+ EBITDA, (d) the stock will be valued at 20x+ EBITDA in perpetuity, and (e) no further dilution will occur. Each of these has perhaps a 70% probability. The compound probability of all five going right is roughly 17%.

Risk Inversion

What could destroy this business?

Scenario 1: Covelya Integration Failure (30% probability) The most dangerous scenario. Sonardyne is a well-established UK business with its own culture, processes, and customer relationships. Kraken is a fast-growing Canadian startup. Merging them requires integrating 12 facilities across multiple continents, 750 employees who did not choose to work for Kraken, and product lines that are complementary on paper but may have conflicting roadmaps in practice. If key Sonardyne engineers leave, if major customers get nervous, if the $10M synergy target proves harder to achieve than expected -- the combined entity could underperform standalone projections for 2-3 years. During that time, the stock (priced for perfection) would reprice violently downward.

Scenario 2: Defense Budget Contraction (15% probability) A geopolitical détente, a change in NATO priorities, or a global recession that forces defense spending cuts could slow the undersea warfare spending boom that Kraken is riding. The company's $2B pipeline is encouraging, but pipeline is not backlog, and backlog is not cash. Defense companies have seen multi-year droughts between contract awards.

Scenario 3: Competitive Leapfrogging (10% probability) Kongsberg, Thales, or a well-funded startup could develop superior SAS technology or an integrated platform that matches Kraken's offering at lower cost. This is unlikely in the near term given qualification timelines, but over 5-10 years, technology moats can erode.

Scenario 4: Dilution Death Spiral (10% probability) If the Covelya deal does not deliver expected returns and Kraken needs additional capital for operations or follow-on acquisitions, further equity raises at potentially lower prices could create a self-reinforcing cycle of dilution and declining share prices.

Combined probability of a severe adverse outcome: ~45%. This is too high for a stock priced at 28-60x EBITDA.

Valuation Philosophy

There is a famous Buffett-ism: "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." But implicit in this wisdom is the corollary: even a wonderful company can be a bad investment at a terrible price.

Kraken may well be a wonderful company in five years. If the Covelya integration succeeds, if combined revenue reaches C$500M+ with 25%+ EBITDA margins, if the TSX and NASDAQ uplistings attract institutional capital, and if the defense spending cycle continues -- then Kraken could be worth C$15-20 per share on 2028-2029 numbers.

But at C$8.42, you are paying 49% above the probability-weighted fair value of C$5.65. You are paying the bull case price for a base case outcome probability. The asymmetry is wrong. The upside to the bull case (C$10.00) is only 19%. The downside to the base case (C$5.50) is 35%. The downside to the bear case (C$2.60) is 69%.

When the downside is 2-4x the upside, you do not buy -- no matter how exciting the technology, how favorable the macro tailwinds, or how bold the CEO's vision. You wait.

The Patient Investor's Path

Here is what I would do:

1. Set a price alert at C$5.00 / US$3.65. This represents ~17x combined 2027E EV/EBITDA -- a reasonable growth premium over defense peers while providing genuine margin of safety.

2. Monitor the Covelya integration through H2 2026. Watch for: combined financial reporting (Q3 2026 earliest), employee retention at Sonardyne, customer cross-selling wins, and whether synergy targets are on track.

3. Watch for the TSX uplisting. This could be a buy-the-rumor-sell-the-news event. If the stock spikes on uplisting and then corrects, that could create an entry point.

4. Be patient. Defense stocks have cycles. The current boom in subsea spending will not last forever. There will be a quarter where orders disappoint, guidance gets cut, or a competitor wins a key contract. That is when the stock will come to you.

The hardest thing in investing is watching a stock go up and not buying it. Kraken has gone from C$1.50 to C$8.42 -- a 460% gain -- in two years. It is tempting to chase. But the math does not support buying at this price. The technology is real. The market opportunity is real. The management team appears competent. But the price is not right.

As Buffett says: "The stock market is a device for transferring money from the impatient to the patient." Be patient. Kraken will still be making the world's best sonar next year. And the year after that. The only question is what price you will pay for the privilege of owning it.

WAIT.